16-75542641-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 3P and 1B. PM2PP5BP4
The NM_001077418.3(TMEM231):c.625G>A(p.Asp209Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000428 in 1,613,714 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001077418.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TMEM231 | NM_001077418.3 | c.625G>A | p.Asp209Asn | missense_variant | 5/7 | ENST00000258173.11 | |
TMEM231 | NM_001077416.2 | c.784G>A | p.Asp262Asn | missense_variant | 4/6 | ||
TMEM231 | NR_074083.2 | n.791G>A | non_coding_transcript_exon_variant | 5/7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TMEM231 | ENST00000258173.11 | c.625G>A | p.Asp209Asn | missense_variant | 5/7 | 1 | NM_001077418.3 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000395 AC: 6AN: 152074Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000682 AC: 17AN: 249258Hom.: 0 AF XY: 0.0000592 AC XY: 8AN XY: 135226
GnomAD4 exome AF: 0.0000431 AC: 63AN: 1461640Hom.: 0 Cov.: 30 AF XY: 0.0000468 AC XY: 34AN XY: 727102
GnomAD4 genome AF: 0.0000395 AC: 6AN: 152074Hom.: 0 Cov.: 31 AF XY: 0.0000538 AC XY: 4AN XY: 74290
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 20, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 08, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 23012439, 27449316, 26477546) - |
Joubert syndrome 20;C3809352:Meckel syndrome, type 11 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 20, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 262 of the TMEM231 protein (p.Asp262Asn). This variant is present in population databases (rs200799769, gnomAD 0.01%). This missense change has been observed in individual(s) with Joubert syndrome (PMID: 23012439, 27449316). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is also known as Asp209Asn. ClinVar contains an entry for this variant (Variation ID: 39822). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. For these reasons, this variant has been classified as Pathogenic. - |
Joubert syndrome and related disorders Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 01, 2023 | Variant summary: TMEM231 c.784G>A (p.Asp262Asn) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 6.8e-05 in 249258 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in TMEM231 causing Joubert Syndrome And Related Disorders (6.8e-05 vs 0.0004), allowing no conclusion about variant significance. c.784G>A has been reported in the literature in multiple individuals affected with Joubert Syndrome And Related Disorders (e.g., Srour_2012, Maglic_2016). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and all laboratories classified the variant as pathogenic (n = 2) or likely pathogenic (n = 1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
TMEM231-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 19, 2024 | The TMEM231 c.784G>A variant is predicted to result in the amino acid substitution p.Asp262Asn. This variant can also be referred to as (NM_001077418.1:c.625G>A (p.Asp209Asn). This variant, along with a protein truncating variant has been previously identified in three individuals with Joubert syndrome (JS) from two different families (Srour et al. 2012. PubMed ID: 23012439). Also, this variant along with an exonic deletion has been reported in three affected individuals with JS (Maglic et al. 2016. PubMed ID: 27449316). This variant is reported in 0.012% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Joubert syndrome 20 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2012 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 16, 2022 | The c.712G>A (p.D238N) alteration is located in exon 4 (coding exon 4) of the TMEM231 gene. This alteration results from a G to A substitution at nucleotide position 712, causing the aspartic acid (D) at amino acid position 238 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at